Pressure BioSciences (PBIO) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	14 Norfolk Avenue
Entity Address, City or Town	South Easton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02375
City Area Code	(508)
Local Phone Number	230-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,074,069

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 121,569	$ 132,311
Accounts receivable	316,796	154,746
Inventories, net of $342,496 reserve at June 30, 2022 and December 31, 2021	1,355,676	1,147,554
Prepaid expenses and other current assets	228,254	422,617
Total current assets	2,022,295	1,857,228
Investment in equity securities	60,604	59,976
Property and equipment, net	101,798	115,846
Right of use asset leases	341,681	395,565
Intangible assets, net	360,577	403,846
TOTAL ASSETS	2,886,955	2,832,461
CURRENT LIABILITIES
Accounts payable	552,691	527,924
Accrued employee compensation	237,102	117,680
Accrued professional fees and other	2,157,575	1,955,672
Other current liabilities	9,036,299	7,757,217
Deferred revenue	31,851	37,124
Convertible debt, net of unamortized discounts of $381,223 and $1,536,649, respectively	15,686,451	12,839,813
Other debt, net of unamortized discounts of $16,900 and $0, respectively	1,621,854	1,256,840
Operating lease liability	138,691	132,996
Other related party debt, net of unamortized discounts of $23,646 and $0, respectively	283,804
Total current liabilities	29,746,318	24,625,266
LONG TERM LIABILITIES
Long term debt	150,000	150,000
Operating lease liability – long term	202,990	262,569
Deferred revenue		3,587
TOTAL LIABILITIES	30,099,308	25,041,422
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS’ DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 10,703,179 and 9,120,526 shares issued and outstanding on June 30, 2022 and December 31, 2021, respectively	107,033	91,206
Warrants to acquire common stock	31,974,888	31,715,154
Additional paid-in capital	64,746,760	64,261,048
Accumulated deficit	(124,042,132)	(118,277,468)
Total stockholders’ deficit	(27,212,353)	(22,208,961)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	2,886,955	2,832,461
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	806	806
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	35	35
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	68	68
Series AA Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred Stock	$ 86	$ 87

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Inventory valuation reserves	$ 342,496	$ 342,496
Other debt, unamortized discounts net	16,900	0
Other related party debt, unamortized discounts net	$ 23,646	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	10,703,179	9,120,526
Common stock, shares, outstanding	10,703,179	9,120,526
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	850	850
Preferred stock, shares issued	300	300
Preferred stock, shares outstanding	300	300
Preferred stock, liquidation preference value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	80,570	80,570
Preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	21	21
Preferred stock, shares issued	21	21
Preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,250	6,250
Preferred stock, shares issued	3,458	3,458
Preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	6,880	6,880
Preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,645	8,649
Preferred stock, shares outstanding	8,645	8,649
Convertible Debt [Member]
Debt instrument, unamortized discount	$ 381,223	$ 1,536,649

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Products, services, other	$ 498,137	$ 608,927	$ 978,137	$ 1,168,801
Total revenue	498,137	608,927	978,137	1,168,801
Costs and expenses:
Cost of products and services	302,141	286,660	616,504	512,935
Research and development	172,726	256,507	454,315	556,450
Selling and marketing	129,434	92,813	195,896	186,141
General and administrative	795,466	619,286	1,699,351	1,634,716
Total operating costs and expenses	1,399,767	1,255,266	2,966,066	2,890,242
Operating loss	(901,630)	(646,339)	(1,987,929)	(1,721,441)
Other (expense) income:
Interest expense, net	(1,835,589)	(3,526,141)	(4,414,750)	(8,194,205)
Unrealized (loss) gain on investment in equity securities	(18,510)	(134,477)	628	(242,380)
Loss on extinguishment of liabilities	(165,277)	(498,226)	(755,127)	(1,223,385)
Other income	4,668	60,012	1,155	58,653
Total other expense	(2,014,708)	(4,098,832)	(5,168,094)	(9,601,317)
Net loss	(2,916,338)	(4,745,171)	(7,156,023)	(11,322,758)
Deemed dividends on beneficial conversion feature				(57,884)
Preferred stock dividends	(431,708)	(404,171)	(863,857)	(807,386)
Net loss attributable to common stockholders	$ (3,348,046)	$ (5,149,342)	$ (8,019,880)	$ (12,188,028)
Basic and diluted net loss per share attributable to common stockholders	$ (0.32)	$ (0.90)	$ (0.80)	$ (2.29)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	10,462,520	5,748,711	10,029,068	5,312,172

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,156,023)	$ (11,322,758)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on loan forgiveness	(10,000)	(367,039)
Non-cash lease expense	53,884	31,624
Common stock and warrants issued for interest and extension fees	1,561,973	4,054,749
Depreciation and amortization	62,207	56,291
Accretion of interest and amortization of debt discount	1,457,204	3,909,024
Loss on extinguishment of accrued liabilities and debt	755,127
Stock-based compensation expense	96,557	124,695
(Gain) loss on investment in equity securities	(628)	242,380
Common stock and warrants issued for services	185,261	238,512
Changes in operating assets and liabilities:
Accounts receivable	(162,050)	(498,538)
Inventories	(208,122)	100,672
Prepaid expenses and other assets	194,363	95,775
Accounts payable	24,767	(143,110)
Accrued employee compensation	119,422	2,932
Operating lease liability	(53,884)	(31,624)
Deferred revenue and other accrued expenses	1,081,750	1,415,688
Net cash used in operating activities	(1,998,192)	(2,090,727)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(4,890)	(3,962)
Net cash used in investing activities	(4,890)	(3,962)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from Series AA Convertible Preferred Stock		100,000
Proceeds from stock option exercises	17,443	14,773
Net proceeds from convertible debt	2,209,750	2,598,250
Net proceeds from non-convertible debt – third party	1,288,100	1,183,188
Net proceeds from non-convertible debt – related party	464,500	171,600
Payments on convertible debt	(865,367)	(1,200,996)
Payments on non-convertible debt – related party	(209,000)	(153,000)
Payments on non-convertible debt – third party	(913,086)	(591,041)
Net cash provided by financing activities	1,992,340	2,122,774
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(10,742)	28,085
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	132,311	18,540
CASH AND CASH EQUIVALENTS AT END OF PERIOD	121,569	46,625
SUPPLEMENTAL INFORMATION
Interest paid in cash	515,210	383,403
NON CASH TRANSACTIONS:
Common stock issued with debt	178,328	112,877
Discount from warrants issued with debt	87,436	1,068,842
Common stock issued in lieu of cash for dividend	215,277	114,298
Early adoption of ASU 2020-06	473,027
Preferred stock dividends	863,857	807,386
Conversion of debt and interest into common stock	350,500	349,350
Discount due to beneficial conversion feature		566,847
Deemed dividend - beneficial conversion feature		57,884
Conversion of preferred stock for common stock	$ 44

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholder's Deficit (Unaudited) - USD ($)	Series D Preferred Stock [Member] Preferred Stock [Member]	Series G Preferred Stock [Member] Preferred Stock [Member]	Series H Preferred Stock [Member] Preferred Stock [Member]	Series H2 Preferred Stock [Member] Preferred Stock [Member]	Series J Preferred Stock [Member] Preferred Stock [Member]	Series K Preferred Stock [Member] Preferred Stock [Member]	Series AA Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 41,683	$ 29,192,471	$ 50,312,968	$ (96,465,807)	$ (16,917,592)
Beginning balance, shares at Dec. 31, 2020	300	80,570	10,000	21	3,458	6,880	8,043	4,168,324
Stock-based compensation										61,237		61,237
Series AA Preferred Stock dividend											(403,215)	(403,215)
Issuance of common stock for services								$ 1,124		237,388		238,512
Issuance of common stock for services, shares								112,400
Conversion of debt and interest for common stock								$ 472		117,528		118,000
Conversion of debt and interest for common stock, shares								47,200
Issuance of common stock for interest paid in kind								$ 9,224		2,012,556		2,021,780
Issuance of common stock for interest paid in kind, shares								922,372
Warrants issued with debt									162,654			162,654
Net loss											(6,577,587)	(6,577,587)
Stock option exercise								$ 214		14,559		14,773
Stock option exercise, shares								21,411
Issuance of warrants for interest paid-in-kind									600,298			600,298
Beneficial conversion feature on debt										53,777		53,777
Series AA Preferred Stock offering									49,884	50,116		100,000
Series AA Preferred Stock offering, shares							40
Beneficial conversion option on convertible preferred stock										57,884		57,884
Deemed dividend on convertible preferred stock										(57,884)		(57,884)
Ending balance, value at Mar. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 52,717	30,005,307	52,860,129	(103,446,609)	(20,527,363)
Ending balance, shares at Mar. 31, 2021	300	80,570	10,000	21	3,458	6,880	8,083	5,271,707
Beginning balance, value at Dec. 31, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 41,683	29,192,471	50,312,968	(96,465,807)	(16,917,592)
Beginning balance, shares at Dec. 31, 2020	300	80,570	10,000	21	3,458	6,880	8,043	4,168,324
Net loss												(11,322,758)
Ending balance, value at Jun. 30, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 62,608	30,911,495	55,317,862	(108,595,951)	(22,302,893)
Ending balance, shares at Jun. 30, 2021	300	80,570	10,000	21	3,458	6,880	8,083	6,260,884
Beginning balance, value at Mar. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 52,717	30,005,307	52,860,129	(103,446,609)	(20,527,363)
Beginning balance, shares at Mar. 31, 2021	300	80,570	10,000	21	3,458	6,880	8,083	5,271,707
Stock-based compensation										63,458		63,458
Series AA Preferred Stock dividend											(404,171)	(404,171)
Conversion of debt and interest for common stock								$ 925		230,325		231,250
Conversion of debt and interest for common stock, shares								92,500
Issuance of common stock for dividends paid-in-kind								$ 560		113,738		114,298
Issuance of common stock for dividends paid-in-kind, shares								56,067
Issuance of common stock for interest paid in kind								$ 7,206		1,425,465		1,432,671
Issuance of common stock for interest paid in kind, shares								720,610
Stock issued with debt								$ 1,200		111,677		112,877
Stock issued with debt, shares								120,000
Warrants issued with debt									906,188			906,188
Net loss											(4,745,171)	(4,745,171)
Beneficial conversion feature on debt										513,070		513,070
Ending balance, value at Jun. 30, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81	$ 62,608	30,911,495	55,317,862	(108,595,951)	(22,302,893)
Ending balance, shares at Jun. 30, 2021	300	80,570	10,000	21	3,458	6,880	8,083	6,260,884
Beginning balance, value at Dec. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87	$ 91,206	31,715,154	64,261,048	(118,277,468)	(22,208,961)
Beginning balance, shares at Dec. 31, 2021	300	80,570	10,000	21	3,458	6,880	8,649	9,120,526
Early adoption of ASU 2020-06										(2,728,243)	2,255,216	(473,027)
Stock-based compensation										64,483		64,483
Series AA Preferred Stock dividend											(432,149)	(432,149)
Issuance of common stock for services								$ 370		77,330		77,700
Issuance of common stock for services, shares								37,000
Issuance of common stock warrants for services									39,761			39,761
Warrants issued for debt extension									132,537			132,537
Common stock issued for debt extension								$ 2,145		470,755		472,900
Common stock issued for debt extension, shares								214,500
Conversion of debt and interest for common stock								$ 1,402		349,098		350,500
Conversion of debt and interest for common stock, shares								140,200
Issuance of common stock for dividends paid-in-kind								$ 318		63,938		64,256
Issuance of common stock for dividends paid-in-kind, shares								31,810
Issuance of common stock for interest paid in kind								$ 5,581		1,167,877		1,173,458
Issuance of common stock for interest paid in kind, shares								558,100
Stock issued with debt								$ 920		141,560		142,480
Stock issued with debt, shares								92,000
Warrants issued with debt									87,436			87,436
Net loss											(4,239,685)	(4,239,685)
Ending balance, value at Mar. 31, 2022	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87	$ 101,942	31,974,888	63,867,846	(120,694,086)	(24,748,311)
Ending balance, shares at Mar. 31, 2022	300	80,570	10,000	21	3,458	6,880	8,649	10,194,136
Beginning balance, value at Dec. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87	$ 91,206	$ 31,715,154	64,261,048	(118,277,468)	(22,208,961)
Beginning balance, shares at Dec. 31, 2021	300	80,570	10,000	21	3,458	6,880	8,649	9,120,526
Net loss												$ (7,156,023)
Stock option exercise, shares												25,279
Ending balance, value at Jun. 30, 2022	$ 3	$ 806	$ 100		$ 35	$ 68	$ 86	$ 107,033	$ 31,974,888	64,746,760	(124,042,132)	$ (27,212,353)
Ending balance, shares at Jun. 30, 2022	300	80,570	10,000	21	3,458	6,880	8,645	10,703,179
Beginning balance, value at Mar. 31, 2022	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87	$ 101,942	31,974,888	63,867,846	(120,694,086)	(24,748,311)
Beginning balance, shares at Mar. 31, 2022	300	80,570	10,000	21	3,458	6,880	8,649	10,194,136
Stock-based compensation										32,074		32,074
Series AA Preferred Stock dividend											(431,708)	(431,708)
Issuance of common stock for services								$ 400		67,400		67,800
Issuance of common stock for services, shares								40,000
Common stock issued for debt extension								$ 1,064		190,239		191,303
Common stock issued for debt extension, shares								106,400
Issuance of common stock for dividends paid-in-kind								$ 865		150,156		151,021
Issuance of common stock for dividends paid-in-kind, shares								86,464
Issuance of common stock for interest paid in kind								$ 2,245		386,270		388,515
Issuance of common stock for interest paid in kind, shares								224,500
Stock issued with debt								$ 220		35,628		35,848
Stock issued with debt, shares								22,000
Net loss											(2,916,338)	(2,916,338)
Stock option exercise								$ 253		17,190		17,443
Stock option exercise, shares								25,279
Conversion of preferred stock for common stock							$ (1)	$ 44		(43)
Conversion of preferred stock for common stock, shares							(4)	4,400
Ending balance, value at Jun. 30, 2022	$ 3	$ 806	$ 100		$ 35	$ 68	$ 86	$ 107,033	$ 31,974,888	$ 64,746,760	$ (124,042,132)	$ (27,212,353)
Ending balance, shares at Jun. 30, 2022	300	80,570	10,000	21	3,458	6,880	8,645	10,703,179

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure Biosciences, Inc. (“we”, “our”, “the Company”) develops and sells innovative, broadly enabling, high pressure-based platform technologies and related consumables for the worldwide life sciences, agriculture, food and beverage, and other key industries. Our solutions are based on the unique properties and/or force generated from either constant (i.e., static) or alternating (i.e., Pressure Cycling Technology™, or “PCT™”) hydrostatic pressure. In the past five years, major new market opportunities have emerged in the use of our pressure-based technologies in: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold™” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology™ (“UST™”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The Company’s initial growth and strong scientific reputation has been generated from PCT, a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). While now focused predominantly on the enormous potential and markets for UST, and secondarily BaroFold, our historical concentration was in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. On February 8, 2021, PBI announced plans to acquire the assets of a global eco-friendly agrochemical supplier. On April 14, 2021, PBI finalized terms and executed a new letter of intent to purchase the assets of the agrochemical supplier. This opportunity offered the potential of producing significant revenue, as well as the potential to apply the UST technology to improve some of the product line. In July 2021, a newly-formed subsidiary of PBI, PBI Agrochem, leased a warehouse in Carson City, NV, and hired a warehouse manager.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of June 30, 2022, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past and as described in Notes 5 and 6. In addition we raised debt and equity capital after June 30, 2022 as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3) Summary of Significant Accounting Policies Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2021. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022. Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting companies financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended Six Months Ended Primary geographical markets 2022 2021 2022 2021 North America $ 253 $ 477 $ 571 $ 685 Europe 2 103 48 187 Asia 243 29 359 297 $ 498 $ 609 $ 978 $ 1,169 1 2 3 4 Three Months Ended Six Months Ended Major products/services lines 2022 2021 2022 2021 Hardware $ 247 $ 336 $ 531 $ 713 Consumables 76 44 116 146 Contract research services 110 136 125 142 Sample preparation accessories 21 40 52 69 Technical support/extended service contracts 36 34 53 58 Agrochem Products - - 83 - Shipping and handling 8 16 18 35 Other - 3 - 6 Revenue $ 498 $ 609 $ 978 $ 1,169 1 2 3 4 Three Months Ended Six Months Ended Timing of revenue recognition 2022 2021 2022 2021 Products transferred at a point in time $ 352 $ 440 $ 800 $ 969 Services transferred over time 146 169 178 200 Revenue $ 498 $ 609 $ 978 $ 1,169 Contract balances Schedule of Contract Balances Contract 32 41 In thousands of US dollars ($) June 30, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 317 $ 155 Contract liabilities (deferred revenue) 32 41 Transaction price allocated to the remaining performance obligations. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 32 $ - $ 32 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three and six months ended June 30, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Top Five Customers 69 % 50 % 61 % 50 % Federal Agencies 0 % 14 % 0 % 8 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, December 31, Top Five Customers 92 % 82 % Federal Agencies 0 % 5 % Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers, who was in fact one of the largest life science instrument manufacturers in the U.S. We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments. Investment in Equity Securities As of June 30, 2022, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”. ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of June 30, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 60,604 628 Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three and six months ended June 30, 2022 and 2021: Schedule of Computation of Loss Per Share For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (3,348,046 ) $ (5,149,342 ) $ (8,019,880 ) $ (12,188,028 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 10,462,520 5,748,711 10,029,068 5,312,172 Loss per common share – basic and diluted $ (0.32 ) $ (0.90 ) $ (0.80 ) $ (2.29 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share As of June 30, 2022 2021 Stock options 1,307,822 1,350,046 Convertible debt 6,102,145 5,083,187 Common stock warrants 16,287,936 15,703,807 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,645,000 8,083,000 Total potentially dilutive shares 32,842,695 30,719,832 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5 The Company recognized stock-based compensation expense of $ 32,074 63,458 96,557 124,695 Schedule of Stock Based Compensation Expense For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of sales $ 2,161 $ 5,107 $ 6,510 $ 10,160 Research and development 9,395 26,491 28,304 52,353 Selling and marketing 4,533 5,887 13,583 10,482 General and administrative 15,985 25,973 48,160 51,700 Total stock-based compensation expense $ 32,074 $ 63,458 $ 96,557 $ 124,695 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at June 30, 2022 using: June 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 60,604 $ 60,604 - - Total Financial Assets $ 60,604 $ 60,604 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $ 6,950 December 31, 2022 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023 7,282 The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term. The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $ 221,432 12% On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 12% Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 115,551 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 447,990 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 2,000 60,000 60,000 49,400 34,400 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	5) Convertible Debt and Other Debt Convertible Debt On various dates during the six months ended June 30, 2022, the Company issued convertible notes for a total of $ 2,624,738 which contained varied terms and conditions including the following: a) 5 - 12 month maturity date; b) interest rates of 12% ; c) convertible to the Company’s common stock at issuance at a fixed rate of $ 2.50 or at variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with either shares of common stock or warrants to purchase common stock that were fair valued at issuance date. The aggregate relative fair value of the shares of common stock and warrants issued with the notes of $ 265,764 was recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment at June 30, 2022. The specific terms of the convertible notes and outstanding balances as of June 30, 2022 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 12 months $ 380,000 $ 98,544 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 $ - June 4, 2019 9 months $ 500,000 $ 302,484 $ - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 12 months $ 115,000 $ 115,000 $ - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ - November 15,2019 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24,2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19,2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17,2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 $ - $ 96,208 April 30,2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18,2020 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12,2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 December 3, 2020 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 $ - $ 36,431 May 6, 2021 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 $ - $ 773,802 June 3, 2021 6 months $ 50,000 $ 50,000 $ 1,500 12 % $ 2.50 $ - $ 7,948 March 1, 2022 8 months $ 700,000 $ 700,000 $ 84,000 12 % (6 ) $ - $ - July 3, 2021 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 February 1,2022 6 months $ 260,000 $ 210,000 $ 10,000 12 % (7 ) $ 2,000 $ - February 4, 2022 8 months $ 500,000 $ 500,000 $ 30,000 12 % (11 ) $ - $ - May 13, 2022 7 months $ 500,000 $ 500,000 $ 25,000 12 % (11 ) $ - $ - January 19,2022 6 months $ 52,000 $ 52,000 $ 2,000 12 % $ 2.50 $ 2,000 $ - January 20,2022 6 months $ 352,188 $ 12,690 $ 45,938 (3 ) (8 ) $ - $ - January 20,2022 6 months $ 352,188 $ 352,188 $ 45,938 (3 ) (8 ) $ - $ - January 20,2022 6 months $ 140,875 $ 140,875 $ 18,375 (3 ) (8 ) $ - $ - August 31, 2021 12 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 September 10, 2021 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) $ - $ 43,520 September 15, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 108,801 September 16, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 112,337 September 24, 2021 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) $ - $ 61,876 September 15, 2021 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 $ - October 21, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ - $ 96,991 December 7, 2021 12 months $ 169,500 $ 67,800 $ 19,500 12 % (10 ) $ 3,750 $ - March 23, 2022 8 months $ 56,500 $ 35,312 $ 6,500 12 % (12 ) $ - $ - March 29, 2022 8 months $ 112,000 $ 67,144 $ 13,000 12 % (12 ) $ - $ - February 9, 2022 12 months $ 88,987 $ 53,487 $ 10,237 12 % (10 ) $ - $ - March 30, 2022 12 months $ 100,000 $ 100,000 $ 5,000 12 % $ 2.50 $ - $ 19,614 April 19, 2022 12 months $ 95,000 $ 95,000 $ - 12 % (12 ) $ - $ 16,234 May 23, 2022 8 months $ 950,000 $ 950,000 $ 57,000 12 % $ 2.50 $ 16,165 $ - May 8, 2022 8 months $ 65,000 $ 65,000 $ 3,000 12 % (7 ) $ - $ - $ 16,067,674 $ 1,775,088 $ 981,665 $ 8,359,812 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lenders have entered into Standstill and Forbearance Agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9% (4) During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion. (7) Notes are convertible before maturity at $ 2.50 (8) Notes can be converted at the lesser of $ 2.50 25% (9) Conversion price of this note is $ 2.50 (10) Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion. (11) Loans can be voluntarily converted before maturity at $ 2.50 2.50 10% (12) Notes are convertible at $ 2.50 75% (13) During the six months ended June 30, 2022, the Company extended nine loans totaling $ 1,650,000 2,872,251 320,900 (14) Lender is a related party. As of June 30, 2022, one lender holds approximately $ 9.4 16.1 For the six months ended June 30, 2022, the Company recognized amortization expense related to the debt discounts indicated above of $ 1,363,151 381,223 Standstill and Forbearance Agreements In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. The Company and two lenders ($ 673,528 In connection to these agreements, the Company incurred interest, penalties, and fees of approximately $ 202,050 404,100 Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the six months ended June 30, 2022 at substantially the same terms for extensions ranging over a period of five to eight months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10% 0.8 The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2022: Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts 2022 Balance at January 1, $ 12,839,813 Early adoption of ASU 2020-06 473,027 Issuance of convertible debt, face value 2,624,738 Deferred financing cost (414,988 ) Debt discount from shares and warrants issued with debt (265,764 ) Payments (865,367 ) Conversion of debt into equity (68,159 ) Accretion of interest and amortization of debt discount to interest expense 1,363,151 Balance at June 30, 15,686,451 Less: current portion 15,686,451 Convertible debt, long-term portion $ – Other Notes On April 29, 2022, the Company borrowed $ 50,000 52 weekly payments 1,250. 42,308 As of June 30, 2022 the Company owes $ 691,500 100,000 3 3.50 On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest. Merchant Agreements We have signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 2.5 5.9 The following table shows our Merchant Agreements as of June 30, 2022: Schedule of Merchant Agreements Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Deferred Finance Fees June 28, 2022 $ 250,000 $ 337,250 $ 248,295 Daily $ 2,595 $ - June 15, 2022 $ 150,000 $ 197,850 $ 141,280 Daily $ 1,522 $ - May 11, 2022 $ 225,000 $ 308,250 $ 181,467 Weekly $ 11,009 $ - January 11, 2022 $ 240,000 $ 300,000 $ 2,456 Weekly $ 11,112 $ - December 21, 2021 $ 400,000 $ 520,000 $ 161,449 Weekly $ 11,305 $ 6,000 $ 1,265,000 $ 1,663,350 $ 734,947 $ 6,000 The following table shows our Merchant Agreements as of December 31, 2021: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly 11,305.00 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily 1,279.00 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500 We have accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. Related Party Notes During the six months ended June 30, 2022, we received short-term non-convertible loans of $ 516,450 12 10 209,000 Long term debt The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75% 731 30

Stockholders_ Deficit

Stockholders’ Deficit	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders’ Deficit	6) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 0.01 1,000,000 1) 20,000 Junior A 2) 313,960 Series A 3) 279,256 Series B 4) 88,098 Series C 5) 850 Series D 6) 500 (“Series E”) 7) 240,000 Series G 8) 10,000 Series H 9) 21 Series H2 10) 6,250 Series J 11) 15,000 Series K 12) 10,000 Series AA As of June 30, 2022, there were no shares of Junior A, and Series A, B, C and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2021 for the pertinent disclosures of preferred stock. Stock Options and Warrants At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 1,307,822 As of June 30, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 76,397 0.62 1.74 1,348,013 The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Weighted Shares price Shares price Shares Total Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 230,000 3.50 230,000 - Exercised (25,279 ) 0.69 - - (25,279 ) - Expired/forfeited - - (149,172 ) $ 3.50 (149,172 ) - Balance outstanding, June 30, 2022 1,307,822 $ 0.72 16,287,936 $ 3.50 17,595,758 17,475,939 As of June 30, 2022, the 1,307,822 0.72 7.22 1,188,003 Common Stock and Warrant Issuances As profiled in the following table, for five loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Issuance Loan Percentage of Loan Defined Shares Issuable Loan Date Principal Principal Issuable Date Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 4 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Loan 5 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly For the three-month and six-month period ended June 30, 2022, the Company is obligated to issue 224,500 782,600 388,515 1,553,765 During the six months ended June 30, 2022, the Company issued a total of 1,582,653 140,200 350,500 782,600 1,561,973 77,000 145,500 118,274 215,277 114,000 178,328 25,279 17,433 320,900 664,203 4 4,400 During the six months ended June 30, 2022, we issued 100,000 three 3.50 87,436 30,000 three 3.50 39,761 100,000 three 3.50 132,537 During the six months ended June 30, 2021, we issued 1,642,982 3.5 112,400 238,512 139,700 349,250 21,411 0.69 56,067 114,298 120,000 112,877 1,374,600 three five 3.50 5.00 1.7

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	7) Subsequent Events From July 1, 2022 through August 8, 2022 the Company borrowed $ 203,000 due upon demand, 10% OID and 12% 180,000 1,868 for 130 days 112,500 618,000 two to six months

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2021. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting companies financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended Six Months Ended Primary geographical markets 2022 2021 2022 2021 North America $ 253 $ 477 $ 571 $ 685 Europe 2 103 48 187 Asia 243 29 359 297 $ 498 $ 609 $ 978 $ 1,169 1 2 3 4 Three Months Ended Six Months Ended Major products/services lines 2022 2021 2022 2021 Hardware $ 247 $ 336 $ 531 $ 713 Consumables 76 44 116 146 Contract research services 110 136 125 142 Sample preparation accessories 21 40 52 69 Technical support/extended service contracts 36 34 53 58 Agrochem Products - - 83 - Shipping and handling 8 16 18 35 Other - 3 - 6 Revenue $ 498 $ 609 $ 978 $ 1,169 1 2 3 4 Three Months Ended Six Months Ended Timing of revenue recognition 2022 2021 2022 2021 Products transferred at a point in time $ 352 $ 440 $ 800 $ 969 Services transferred over time 146 169 178 200 Revenue $ 498 $ 609 $ 978 $ 1,169 Contract balances Schedule of Contract Balances Contract 32 41 In thousands of US dollars ($) June 30, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 317 $ 155 Contract liabilities (deferred revenue) 32 41 Transaction price allocated to the remaining performance obligations. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 32 $ - $ 32 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three and six months ended June 30, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Top Five Customers 69 % 50 % 61 % 50 % Federal Agencies 0 % 14 % 0 % 8 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, December 31, Top Five Customers 92 % 82 % Federal Agencies 0 % 5 %
Product Supply	Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers, who was in fact one of the largest life science instrument manufacturers in the U.S. We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.
Investment in Equity Securities	Investment in Equity Securities As of June 30, 2022, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”. ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of June 30, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 60,604 628
Computation of Loss per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three and six months ended June 30, 2022 and 2021: Schedule of Computation of Loss Per Share For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (3,348,046 ) $ (5,149,342 ) $ (8,019,880 ) $ (12,188,028 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 10,462,520 5,748,711 10,029,068 5,312,172 Loss per common share – basic and diluted $ (0.32 ) $ (0.90 ) $ (0.80 ) $ (2.29 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share As of June 30, 2022 2021 Stock options 1,307,822 1,350,046 Convertible debt 6,102,145 5,083,187 Common stock warrants 16,287,936 15,703,807 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,645,000 8,083,000 Total potentially dilutive shares 32,842,695 30,719,832
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5 The Company recognized stock-based compensation expense of $ 32,074 63,458 96,557 124,695 Schedule of Stock Based Compensation Expense For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of sales $ 2,161 $ 5,107 $ 6,510 $ 10,160 Research and development 9,395 26,491 28,304 52,353 Selling and marketing 4,533 5,887 13,583 10,482 General and administrative 15,985 25,973 48,160 51,700 Total stock-based compensation expense $ 32,074 $ 63,458 $ 96,557 $ 124,695
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at June 30, 2022 using: June 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 60,604 $ 60,604 - - Total Financial Assets $ 60,604 $ 60,604 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended Six Months Ended Primary geographical markets 2022 2021 2022 2021 North America $ 253 $ 477 $ 571 $ 685 Europe 2 103 48 187 Asia 243 29 359 297 $ 498 $ 609 $ 978 $ 1,169 1 2 3 4 Three Months Ended Six Months Ended Major products/services lines 2022 2021 2022 2021 Hardware $ 247 $ 336 $ 531 $ 713 Consumables 76 44 116 146 Contract research services 110 136 125 142 Sample preparation accessories 21 40 52 69 Technical support/extended service contracts 36 34 53 58 Agrochem Products - - 83 - Shipping and handling 8 16 18 35 Other - 3 - 6 Revenue $ 498 $ 609 $ 978 $ 1,169 1 2 3 4 Three Months Ended Six Months Ended Timing of revenue recognition 2022 2021 2022 2021 Products transferred at a point in time $ 352 $ 440 $ 800 $ 969 Services transferred over time 146 169 178 200 Revenue $ 498 $ 609 $ 978 $ 1,169
Schedule of Contract Balances	Contract balances Schedule of Contract Balances Contract 32 41 In thousands of US dollars ($) June 30, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 317 $ 155 Contract liabilities (deferred revenue) 32 41
Schedule of Future Related to Performance Obligations	Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 32 $ - $ 32
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three and six months ended June 30, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Top Five Customers 69 % 50 % 61 % 50 % Federal Agencies 0 % 14 % 0 % 8 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, December 31, Top Five Customers 92 % 82 % Federal Agencies 0 % 5 %
Schedule of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the three and six months ended June 30, 2022 and 2021: Schedule of Computation of Loss Per Share For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (3,348,046 ) $ (5,149,342 ) $ (8,019,880 ) $ (12,188,028 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 10,462,520 5,748,711 10,029,068 5,312,172 Loss per common share – basic and diluted $ (0.32 ) $ (0.90 ) $ (0.80 ) $ (2.29 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share As of June 30, 2022 2021 Stock options 1,307,822 1,350,046 Convertible debt 6,102,145 5,083,187 Common stock warrants 16,287,936 15,703,807 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,645,000 8,083,000 Total potentially dilutive shares 32,842,695 30,719,832
Schedule of Stock Based Compensation Expense	Schedule of Stock Based Compensation Expense For the Three Months Ended For the Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of sales $ 2,161 $ 5,107 $ 6,510 $ 10,160 Research and development 9,395 26,491 28,304 52,353 Selling and marketing 4,533 5,887 13,583 10,482 General and administrative 15,985 25,973 48,160 51,700 Total stock-based compensation expense $ 32,074 $ 63,458 $ 96,557 $ 124,695
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at June 30, 2022 using: June 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 60,604 $ 60,604 - - Total Financial Assets $ 60,604 $ 60,604 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 115,551 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 447,990

Convertible Debt and Other De_2

Convertible Debt and Other Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of June 30, 2022 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 12 months $ 380,000 $ 98,544 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 $ - June 4, 2019 9 months $ 500,000 $ 302,484 $ - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 12 months $ 115,000 $ 115,000 $ - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ - November 15,2019 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24,2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19,2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11,2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17,2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 $ - $ 96,208 April 30,2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18,2020 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12,2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 December 3, 2020 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 $ - $ 36,431 May 6, 2021 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 $ - $ 773,802 June 3, 2021 6 months $ 50,000 $ 50,000 $ 1,500 12 % $ 2.50 $ - $ 7,948 March 1, 2022 8 months $ 700,000 $ 700,000 $ 84,000 12 % (6 ) $ - $ - July 3, 2021 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 February 1,2022 6 months $ 260,000 $ 210,000 $ 10,000 12 % (7 ) $ 2,000 $ - February 4, 2022 8 months $ 500,000 $ 500,000 $ 30,000 12 % (11 ) $ - $ - May 13, 2022 7 months $ 500,000 $ 500,000 $ 25,000 12 % (11 ) $ - $ - January 19,2022 6 months $ 52,000 $ 52,000 $ 2,000 12 % $ 2.50 $ 2,000 $ - January 20,2022 6 months $ 352,188 $ 12,690 $ 45,938 (3 ) (8 ) $ - $ - January 20,2022 6 months $ 352,188 $ 352,188 $ 45,938 (3 ) (8 ) $ - $ - January 20,2022 6 months $ 140,875 $ 140,875 $ 18,375 (3 ) (8 ) $ - $ - August 31, 2021 12 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 September 10, 2021 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) $ - $ 43,520 September 15, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 108,801 September 16, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) $ - $ 112,337 September 24, 2021 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) $ - $ 61,876 September 15, 2021 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 $ - October 21, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ - $ 96,991 December 7, 2021 12 months $ 169,500 $ 67,800 $ 19,500 12 % (10 ) $ 3,750 $ - March 23, 2022 8 months $ 56,500 $ 35,312 $ 6,500 12 % (12 ) $ - $ - March 29, 2022 8 months $ 112,000 $ 67,144 $ 13,000 12 % (12 ) $ - $ - February 9, 2022 12 months $ 88,987 $ 53,487 $ 10,237 12 % (10 ) $ - $ - March 30, 2022 12 months $ 100,000 $ 100,000 $ 5,000 12 % $ 2.50 $ - $ 19,614 April 19, 2022 12 months $ 95,000 $ 95,000 $ - 12 % (12 ) $ - $ 16,234 May 23, 2022 8 months $ 950,000 $ 950,000 $ 57,000 12 % $ 2.50 $ 16,165 $ - May 8, 2022 8 months $ 65,000 $ 65,000 $ 3,000 12 % (7 ) $ - $ - $ 16,067,674 $ 1,775,088 $ 981,665 $ 8,359,812 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lenders have entered into Standstill and Forbearance Agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9% (4) During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion. (7) Notes are convertible before maturity at $ 2.50 (8) Notes can be converted at the lesser of $ 2.50 25% (9) Conversion price of this note is $ 2.50 (10) Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion. (11) Loans can be voluntarily converted before maturity at $ 2.50 2.50 10% (12) Notes are convertible at $ 2.50 75% (13) During the six months ended June 30, 2022, the Company extended nine loans totaling $ 1,650,000 2,872,251 320,900 (14) Lender is a related party.
Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2022: Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts 2022 Balance at January 1, $ 12,839,813 Early adoption of ASU 2020-06 473,027 Issuance of convertible debt, face value 2,624,738 Deferred financing cost (414,988 ) Debt discount from shares and warrants issued with debt (265,764 ) Payments (865,367 ) Conversion of debt into equity (68,159 ) Accretion of interest and amortization of debt discount to interest expense 1,363,151 Balance at June 30, 15,686,451 Less: current portion 15,686,451 Convertible debt, long-term portion $ –
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of June 30, 2022: Schedule of Merchant Agreements Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Deferred Finance Fees June 28, 2022 $ 250,000 $ 337,250 $ 248,295 Daily $ 2,595 $ - June 15, 2022 $ 150,000 $ 197,850 $ 141,280 Daily $ 1,522 $ - May 11, 2022 $ 225,000 $ 308,250 $ 181,467 Weekly $ 11,009 $ - January 11, 2022 $ 240,000 $ 300,000 $ 2,456 Weekly $ 11,112 $ - December 21, 2021 $ 400,000 $ 520,000 $ 161,449 Weekly $ 11,305 $ 6,000 $ 1,265,000 $ 1,663,350 $ 734,947 $ 6,000 The following table shows our Merchant Agreements as of December 31, 2021: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly 11,305.00 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily 1,279.00 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Weighted Shares price Shares price Shares Total Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 230,000 3.50 230,000 - Exercised (25,279 ) 0.69 - - (25,279 ) - Expired/forfeited - - (149,172 ) $ 3.50 (149,172 ) - Balance outstanding, June 30, 2022 1,307,822 $ 0.72 16,287,936 $ 3.50 17,595,758 17,475,939
Schedule of Loans Obligated to Issue Shares	As profiled in the following table, for five loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Issuance Loan Percentage of Loan Defined Shares Issuable Loan Date Principal Principal Issuable Date Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 4 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Loan 5 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Product Information [Line Items]
Revenue	$ 498,137	$ 608,927	$ 978,137	$ 1,168,801
Transferred at Point in Time [Member]
Product Information [Line Items]
Revenue	352,000	440,000	800,000	969,000
Transferred over Time [Member]
Product Information [Line Items]
Revenue	146,000	169,000	178,000	200,000
Hardware [Member]
Product Information [Line Items]
Revenue	247,000	336,000	531,000	713,000
Consumables [Member]
Product Information [Line Items]
Revenue	76,000	44,000	116,000	146,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue	110,000	136,000	125,000	142,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	21,000	40,000	52,000	69,000
Technical Support/Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	36,000	34,000	53,000	58,000
Agrochem Products [Member]
Product Information [Line Items]
Revenue			83,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	8,000	16,000	18,000	35,000
Others [Member]
Product Information [Line Items]
Revenue		3,000		6,000
North America [Member]
Product Information [Line Items]
Revenue	253,000	477,000	571,000	685,000
Europe [Member]
Product Information [Line Items]
Revenue	2,000	103,000	48,000	187,000
Asia [Member]
Product Information [Line Items]
Revenue	$ 243,000	$ 29,000	$ 359,000	$ 297,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 317	$ 155
Contract liabilities (deferred revenue)	$ 32	$ 41

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 32
2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	32
2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	69%	50%	61%	50%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage			92%		82%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	0%	14%	0%	8%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage			0%		5%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Accounting Policies [Abstract]
Net loss attributable to common stockholders	$ (3,348,046)	$ (5,149,342)	$ (8,019,880)	$ (12,188,028)
Weighted average common stock shares outstanding	10,462,520	5,748,711	10,029,068	5,312,172
Loss per common share – basic and diluted	$ (0.32)	$ (0.90)	$ (0.80)	$ (2.29)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	32,842,695	30,719,832
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	1,307,822	1,350,046
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	6,102,145	5,083,187
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	16,287,936	15,703,807
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	26,857	26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	115,267	115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	229,334	229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,645,000	8,083,000

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total stock-based compensation expense	$ 32,074	$ 63,458	$ 96,557	$ 124,695
Cost of Sales [Member]
Total stock-based compensation expense	2,161	5,107	6,510	10,160
Research and Development Expense [Member]
Total stock-based compensation expense	9,395	26,491	28,304	52,353
Selling and Marketing Expense [Member]
Total stock-based compensation expense	4,533	5,887	13,583	10,482
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 15,985	$ 25,973	$ 48,160	$ 51,700

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Financing Receivable, Past Due [Line Items]
Total Financial Assets	$ 60,604	$ 59,976
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	60,604	59,976
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	60,604	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	60,604	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 01, 2022	Dec. 31, 2021
Cumulative effect of adoption, adjustment in additional paid in capital	$ 64,746,760		$ 64,746,760			$ 64,261,048
Cumulative effect of adoption, adjustment in accumulated deficit	$ (124,042,132)		$ (124,042,132)			$ (118,277,468)
Forfeiture rate	5%		5%
Share based compensation	$ 32,074	$ 63,458	$ 96,557	$ 124,695
Nexity Global SA [Member]
Sale of stock, number of shares issued in transaction			100,250
Investment owned fair value	$ 60,604		$ 60,604
Marketable securities realized gain loss			$ 628
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative effect of adoption, adjustment in additional paid in capital					$ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit					$ 2,255,216

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Jun. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 115,551
2023	149,299
2024	64,393
2025	66,969
2026	51,778
Thereafter
Total	$ 447,990

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended		12 Months Ended
	Aug. 09, 2021	Apr. 30, 2012	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Battelle Memorial Institute [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fees						$ 5,000	$ 4,000	$ 3,000	$ 2,000	$ 1,200
Target Discovery Inc [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fees			$ 60,000		$ 60,000
Payments for fees		$ 1,400	$ 49,400	$ 34,400
Professional and contract services expense		$ 2,000
Medford lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease expire date			Dec. 30, 2023
Annual cost of living payment			$ 7,282
Lessee operating lease description			The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term.
Operating lease liability			$ 221,432
Estimated borrowing rate			12%
Sparks lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lessee operating lease description	On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term
Operating lease liability			$ 239,327
Estimated borrowing rate			12%
Corporate Office [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease monthly payments			$ 6,950
Lease expire date			Dec. 31, 2022

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details)	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares
Line of Credit Facility [Line Items]
Convertible Debt	$ 15,686,451
Original issue discount	68,159
Fixed Rate Convertible Notes [Member]
Line of Credit Facility [Line Items]
Convertible Debt	16,067,674
Original issue discount	1,775,088
Deferred finance fees	981,665
Discount for conversion feaure and warrants/shares	$ 8,359,812
Convertible Notes One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 380,000
Convertible Debt	98,544
Original issue discount	$ 15,200
Debt conversion interest rate percentage	8%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 15,200
Discount for conversion feaure and warrants/shares	$ 332,407
Inception date	May 17, 2018	[1],[2]
Convertible Notes Two [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Original issue discount	$ 2,500
Debt conversion interest rate percentage	24%
Debt conversion price | $ / shares	$ 7.50
Deferred finance fees	$ 2,500
Discount for conversion feaure and warrants/shares
Inception date	Jan. 03, 2019	[2],[3]
Convertible Notes Three [Member]
Line of Credit Facility [Line Items]
Term	9 months
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	302,484
Original issue discount
Debt conversion interest rate percentage	8%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 40,500
Discount for conversion feaure and warrants/shares	$ 70,631
Inception date	Jun. 04, 2019	[1],[2]
Convertible Notes Four [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Original issue discount
Debt conversion interest rate percentage	4%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 5,750
Discount for conversion feaure and warrants/shares	$ 15,460
Inception date	Jul. 19, 2019	[1],[2]
Convertible Notes Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 78,750
Convertible Debt	78,750
Original issue discount
Debt conversion interest rate percentage	4%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 3,750
Discount for conversion feaure and warrants/shares	$ 13,759
Inception date	Sep. 27, 2019	[1],[2]
Convertible Notes Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 78,750
Convertible Debt	78,750
Original issue discount
Debt conversion interest rate percentage	4%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 3,750
Discount for conversion feaure and warrants/shares
Inception date	Oct. 24, 2019	[1],[2]
Convertible Notes Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 385,000
Convertible Debt	320,000
Original issue discount	$ 35,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 35,000
Discount for conversion feaure and warrants/shares	$ 90,917
Inception date	Nov. 15, 2019	[2]
Convertible Notes Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 330,000
Convertible Debt	330,000
Original issue discount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 30,000
Discount for conversion feaure and warrants/shares	$ 91,606
Inception date	Jan. 02, 2020	[2]
Convertible Notes Nine [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 247,500
Convertible Debt	247,500
Original issue discount	$ 22,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 22,500
Discount for conversion feaure and warrants/shares	$ 89,707
Inception date	Jan. 24, 2020	[2]
Convertible Notes Ten [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 363,000
Convertible Debt	363,000
Original issue discount	$ 33,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 33,000
Discount for conversion feaure and warrants/shares	$ 297,000
Inception date	Jan. 29, 2020	[2]
Convertible Notes Eleven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 275,000
Convertible Debt	275,000
Original issue discount	$ 25,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 25,000
Discount for conversion feaure and warrants/shares	$ 225,000
Inception date	Feb. 12, 2020	[2]
Convertible Notes Twelve [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 165,000
Convertible Debt	165,000
Original issue discount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 15,000
Discount for conversion feaure and warrants/shares	$ 135,000
Inception date	Feb. 19, 2020	[2]
Convertible Notes Thirteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 330,000
Convertible Debt	330,000
Original issue discount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 30,000
Discount for conversion feaure and warrants/shares	$ 232,810
Inception date	Mar. 11, 2020	[2]
Convertible Notes Fourteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 165,000
Convertible Debt	165,000
Original issue discount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 15,000
Discount for conversion feaure and warrants/shares	$ 60,705
Inception date	Mar. 13, 2020	[2]
Convertible Notes Fifteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 111,100
Convertible Debt	111,100
Original issue discount	$ 10,100
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 10,100
Discount for conversion feaure and warrants/shares	$ 90,900
Inception date	Mar. 26, 2020	[2]
Convertible Notes Sixteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 276,100
Convertible Debt	276,100
Original issue discount	$ 25,100
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 25,000
Discount for conversion feaure and warrants/shares	$ 221,654
Inception date	Apr. 08, 2020	[2]
Convertible Notes Seventeen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 143,750
Convertible Debt	143,750
Original issue discount	$ 18,750
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 96,208
Inception date	Apr. 17, 2020	[2]
Convertible Notes Eighteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 546,250
Convertible Debt	546,250
Original issue discount	$ 71,250
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 47,500
Discount for conversion feaure and warrants/shares	$ 427,500
Inception date	Apr. 30, 2020	[2]
Convertible Notes Nineteen [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 460,000
Convertible Debt	460,000
Original issue discount	$ 60,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 40,000
Discount for conversion feaure and warrants/shares	$ 360,000
Inception date	May 06, 2020	[2]
Convertible Notes Twenty [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 546,250
Convertible Debt	221,250
Original issue discount	$ 46,250
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 35,500
Discount for conversion feaure and warrants/shares	$ 439,500
Inception date	May 18, 2020	[2]
Convertible Notes Twenty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 902,750
Convertible Debt	652,750
Original issue discount	$ 92,750
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 58,900
Discount for conversion feaure and warrants/shares	$ 708,500
Inception date	Jun. 02, 2020	[2]
Convertible Notes Twenty Two [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 57,500
Convertible Debt	57,500
Original issue discount	$ 7,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 5,000
Discount for conversion feaure and warrants/shares	$ 45,000
Inception date	Jun. 12, 2020	[2]
Convertible Notes Twenty Three [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 138,000
Convertible Debt	138,000
Original issue discount	$ 18,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 12,000
Discount for conversion feaure and warrants/shares	$ 108,000
Inception date	Jun. 22, 2020	[2]
Convertible Notes Twenty Four [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 586,500
Convertible Debt	586,500
Original issue discount	$ 76,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 51,000
Discount for conversion feaure and warrants/shares	$ 400,234
Inception date	Jul. 07, 2020	[2]
Convertible Notes Twenty Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 362,250
Convertible Debt	362,250
Original issue discount	$ 47,250
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 31,500
Discount for conversion feaure and warrants/shares	$ 185,698
Inception date	Jul. 17, 2020	[2]
Convertible Notes Twenty Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 345,000
Convertible Debt	345,000
Original issue discount	$ 45,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 30,000
Discount for conversion feaure and warrants/shares	$ 241,245
Inception date	Jul. 29, 2020	[2]
Convertible Notes Twenty Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Original issue discount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 10,000
Discount for conversion feaure and warrants/shares	$ 24,875
Inception date	Jul. 21, 2020	[2],[4]
Convertible Notes Twenty Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 762,450
Convertible Debt	462,450
Original issue discount	$ 69,450
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 66,300
Discount for conversion feaure and warrants/shares	$ 580,124
Inception date	Aug. 14, 2020	[2]
Convertible Notes Twenty Nine [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 391,000
Convertible Debt	391,000
Original issue discount	$ 51,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 34,000
Discount for conversion feaure and warrants/shares	$ 231,043
Inception date	Sep. 10, 2020	[2]
Convertible Notes Thirty [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 345,000
Convertible Debt	345,000
Original issue discount	$ 45,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 30,000
Discount for conversion feaure and warrants/shares	$ 66,375
Inception date	Sep. 21, 2020	[2],[4]
Convertible Notes Thirty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	15,000
Original issue discount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 10,000
Discount for conversion feaure and warrants/shares	$ 20,500
Inception date	Sep. 23, 2020	[2]
Convertible Notes Thirty Two [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 299,000
Convertible Debt	299,000
Original issue discount	$ 39,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 26,000
Discount for conversion feaure and warrants/shares	$ 197,882
Inception date	Dec. 03, 2020	[2]
Convertible Notes Thirty Three [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Original issue discount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 10,000
Discount for conversion feaure and warrants/shares	$ 18,875
Inception date	Oct. 22, 2020	[2],[4]
Convertible Notes Thirty Four [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 230,000
Convertible Debt	230,000
Original issue discount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 20,000
Discount for conversion feaure and warrants/shares	$ 180,000
Inception date	Feb. 17, 2021	[2]
Convertible Notes Thirty Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 55,000
Convertible Debt	55,000
Original issue discount	$ 5,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 36,431
Inception date	Mar. 23, 2021	[2]
Convertible Notes Thirty Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 402,500
Convertible Debt	402,500
Original issue discount	$ 52,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 35,000
Discount for conversion feaure and warrants/shares	$ 312,551
Inception date	May 06, 2021	[2]
Convertible Notes Thirty Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 230,000
Convertible Debt	230,000
Original issue discount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 20,000
Discount for conversion feaure and warrants/shares	$ 144,760
Inception date	Jun. 17, 2021	[2]
Convertible Notes Thirty Eight [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 977,500
Convertible Debt	977,500
Original issue discount	$ 127,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 773,802
Inception date	Jun. 25, 2021	[2]
Convertible Notes Thirty Nine [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Original issue discount	$ 1,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 7,948
Inception date	Jun. 03, 2021	[2]
Convertible Notes Fourty [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 700,000
Convertible Debt	700,000
Original issue discount	$ 84,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (6)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Mar. 01, 2022	[5]
Convertible Notes Fourty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Original issue discount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 10,000
Discount for conversion feaure and warrants/shares	$ 90,000
Inception date	Jul. 03, 2021	[2]
Convertible Notes Fourty Two [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 260,000
Convertible Debt	210,000
Original issue discount	$ 10,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees	$ 2,000
Discount for conversion feaure and warrants/shares
Inception date	Feb. 01, 2022	[2],[5]
Convertible Notes Fourty Three [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	500,000
Original issue discount	$ 30,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (11)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Feb. 04, 2022	[5]
Convertible Notes Fourty Four [Member]
Line of Credit Facility [Line Items]
Term	7 months
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	500,000
Original issue discount	$ 25,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (11)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	May 13, 2022	[5]
Convertible Notes Fourty Five [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 52,000
Convertible Debt	52,000
Original issue discount	$ 2,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 2,000
Discount for conversion feaure and warrants/shares
Inception date	Jan. 19, 2022	[2],[5]
Convertible Notes Fourty Six [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 352,188
Convertible Debt	12,690
Original issue discount	$ 45,938
Debt conversion interest rate percentage	(3.00%)
Debt conversion price | $ / shares	$ (8)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Jan. 20, 2022	[2],[5],[6]
Convertible Notes Fourty Seven [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 352,188
Convertible Debt	352,188
Original issue discount	$ 45,938
Debt conversion interest rate percentage	(3.00%)
Debt conversion price | $ / shares	$ (8)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Jan. 20, 2022	[2],[5],[6]
Convertible Notes Fourty Eight [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 140,875
Convertible Debt	140,875
Original issue discount	$ 18,375
Debt conversion interest rate percentage	(3.00%)
Debt conversion price | $ / shares	$ (8)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Jan. 20, 2022	[2],[5],[6]
Convertible Notes Fourty Nine [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Original issue discount	$ 24,750
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ (9)
Deferred finance fees	$ 16,500
Discount for conversion feaure and warrants/shares	$ 148,500
Inception date	Aug. 31, 2021	[2]
Convertible Notes Fifty [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 100,000
Convertible Debt	100,000
Original issue discount	$ 4,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 43,520
Inception date	Sep. 10, 2021	[2]
Convertible Notes Fifty One [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Original issue discount	$ 12,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 108,801
Inception date	Sep. 15, 2021	[2]
Convertible Notes Fifty Two [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Original issue discount	$ 12,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 112,337
Inception date	Sep. 16, 2021	[2]
Convertible Notes Fifty Three [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 125,000
Convertible Debt	125,000
Original issue discount	$ 6,250
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 61,876
Inception date	Sep. 24, 2021	[2]
Convertible Notes Fifty Four [Member]
Line of Credit Facility [Line Items]
Term	6 months
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Original issue discount	$ 37,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees	$ 30,000
Discount for conversion feaure and warrants/shares
Inception date	Sep. 15, 2021	[2]
Convertible Notes Fifty Five [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Original issue discount	$ 24,750
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 16,500
Discount for conversion feaure and warrants/shares	$ 87,332
Inception date	Oct. 21, 2021	[4]
Convertible Notes Fifty Six [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Original issue discount	$ 24,750
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 96,991
Inception date	Nov. 01, 2021	[4]
Convertible Notes Fifty Seven [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 169,500
Convertible Debt	67,800
Original issue discount	$ 19,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (10)
Deferred finance fees	$ 3,750
Discount for conversion feaure and warrants/shares
Inception date	Dec. 07, 2021
Convertible Notes Fifty Eight [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 56,500
Convertible Debt	35,312
Original issue discount	$ 6,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Mar. 23, 2022
Convertible Notes Fifty Nine [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 112,000
Convertible Debt	67,144
Original issue discount	$ 13,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Mar. 29, 2022
Convertible Notes Sixty [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 88,987
Convertible Debt	53,487
Original issue discount	$ 10,237
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (10)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	Feb. 09, 2022
Convertible Notes Sixty One [Member]
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 100,000
Convertible Debt	100,000
Original issue discount	$ 5,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 19,614
Inception date	Mar. 30, 2022
Convertible Notes Sixty Two [Member
Line of Credit Facility [Line Items]
Term	12 months
Debt Instrument, Face Amount	$ 95,000
Convertible Debt	95,000
Original issue discount
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Deferred finance fees
Discount for conversion feaure and warrants/shares	$ 16,234
Inception date	Apr. 19, 2022
Convertible Notes Sixty Three [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 950,000
Convertible Debt	950,000
Original issue discount	$ 57,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Deferred finance fees	$ 16,165
Discount for conversion feaure and warrants/shares
Inception date	May 23, 2022
Convertible Notes Sixty Four [Member]
Line of Credit Facility [Line Items]
Term	8 months
Debt Instrument, Face Amount	$ 65,000
Convertible Debt	65,000
Original issue discount	$ 3,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Deferred finance fees
Discount for conversion feaure and warrants/shares
Inception date	May 08, 2022	[5],[7]
[1]The Company and lenders have entered into Standstill and Forbearance Agreements (as described below).[2]The Note is past due. The Company and the lender are negotiating in good faith to extend the loan.[3]During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate.[4]The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date.[5]During the six months ended June 30, 2022, the Company extended nine loans totaling $ 1,650,000 2,872,251 320,900 40.9%

Schedule of Convertible Debts_2

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) - USD ($)		6 Months Ended
	Oct. 01, 2019	Jun. 30, 2022
Short-Term Debt [Line Items]
Debt instrument lowest trading price		25%
Debt instrument, description	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Debt instrument, convertible price per shares		$ 2.50
Debt instrument, convertible, conversion price		$ 2.50
Debt instrument conversion ratio		0.10
Debt default convertible conversion ratio		75%
Nine Loans [Member]
Short-Term Debt [Line Items]
Proceeds from loans		$ 1,650,000
Increase in principal amount		$ 2,872,251
Nine Loans [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Shares issued, shares		320,900
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Debt instrument, description		Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion.
PBI Agrochem Inc [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price		40.90%

Summary of Changes in Convertib

Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Balance at January 1,	$ 12,839,813
Early adoption of ASU 2020-06	473,027
Issuance of convertible debt, face value	2,624,738
Deferred financing cost	(414,988)
Debt discount from shares and warrants issued with debt	(265,764)
Payments	(865,367)
Conversion of debt into equity	(68,159)
Accretion of interest and amortization of debt discount to interest expense	1,363,151
Convertible Debt	15,686,451
Less: current portion	15,686,451
Convertible debt, long-term portion

Schedule of Merchant Agreements

Schedule of Merchant Agreements (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price		$ 525,000
Purchased Amount		686,250
Outstanding Balance		398,910
Deferred finance fees		8,500
Merchant Agreements One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 250,000	400,000
Purchased Amount	337,250	520,000
Outstanding Balance	$ 248,295	$ 390,120
Debt Instrument, Frequency of Periodic Payment	Daily	Weekly
Debt Instrument, Periodic Payment	$ 2,595	$ 11,305
Deferred finance fees		$ 6,000
Inception date	Jun. 28, 2022	Dec. 21, 2021
Merchant Agreements Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 150,000	$ 125,000
Purchased Amount	197,850	166,250
Outstanding Balance	$ 141,280	$ 8,790
Debt Instrument, Frequency of Periodic Payment	Daily	Daily
Debt Instrument, Periodic Payment	$ 1,522	$ 1,279
Deferred finance fees		$ 2,500
Inception date	Jun. 15, 2022	Jul. 06, 2021
Merchant Agreements Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 225,000
Purchased Amount	308,250
Outstanding Balance	$ 181,467
Debt Instrument, Frequency of Periodic Payment	Weekly
Debt Instrument, Periodic Payment	$ 11,009
Deferred finance fees
Inception date	May 11, 2022
Merchant Agreements Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 240,000
Purchased Amount	300,000
Outstanding Balance	$ 2,456
Debt Instrument, Frequency of Periodic Payment	Weekly
Debt Instrument, Periodic Payment	$ 11,112
Deferred finance fees
Inception date	Jan. 11, 2022
Merchant Agreements Five [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 400,000
Purchased Amount	520,000
Outstanding Balance	$ 161,449
Debt Instrument, Frequency of Periodic Payment	Weekly
Debt Instrument, Periodic Payment	$ 11,305
Deferred finance fees	$ 6,000
Inception date	Dec. 21, 2021

Convertible Debt and Other De_3

Convertible Debt and Other Debt (Details Narrative) - USD ($)			3 Months Ended	6 Months Ended
	Apr. 29, 2022	Oct. 01, 2019	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Short-Term Debt [Line Items]
Proceeds from issuance of convertible notes				$ 2,209,750	$ 2,598,250
Debt Instrument, Convertible, Conversion Price			$ 2.50	$ 2.50
Convertible note outstanding			$ 15,686,451	$ 15,686,451		$ 12,839,813
Losses on extinguishment of debt				(755,127)
Proceeds from related party debt				464,500	171,600
Outstanding balance			42,308	42,308
Debt instrument, description		On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Repayment of related party debt				209,000	$ 153,000
Standstill and Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Convertible note outstanding			673,528	673,528
Company incurred interest, penalties, and fees			$ 202,050	$ 404,100
Economic Injury Disaster Loan Program [Member]
Short-Term Debt [Line Items]
Debt term				30 years
Debt instrument interest rate			3.75%	3.75%
Monthly payments for principal and interest				$ 731
Debt instrument, face amount			$ 150,000	150,000
One Lender [Member]
Short-Term Debt [Line Items]
Convertible note outstanding			9,400,000	9,400,000
Lender [Member]
Short-Term Debt [Line Items]
Convertible note outstanding			$ 16,100,000	$ 16,100,000
Minimum [Member] | Merchant Agreements [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate			2.50%	2.50%
Maximum [Member] | Merchant Agreements [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate			5.90%	5.90%
Convertible Debt [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of convertible notes			$ 2,624,738
Amortization of debt discount				$ 1,363,151
Convertible Debt [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Debt Instrument, Convertible, Conversion Price			$ 2.50	$ 2.50
Convertible Debt, Fair Value Disclosures			$ 265,764	$ 265,764
Convertible Debt [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt term				5 months
Convertible Debt [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt term				12 months
Debt instrument interest rate			12%	12%
Convertible Debentures and Other Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt instrument, unamortized discount			$ 381,223	$ 381,223
New Loan [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate			10%	10%
Losses on extinguishment of debt				$ 800,000
Other Notes [Member]
Short-Term Debt [Line Items]
Proceeds from related party debt	$ 50,000
Frequency of periodic payment	52 weekly payments
Monthly payments for principal and interest	$ 1,250
Notes 2 [Member] | Private Investor [Member]
Short-Term Debt [Line Items]
Debt owes			$ 691,500	$ 691,500
Warrants issued			100,000	100,000
Warrants term			3 years	3 years
Warrants price			$ 3.50	$ 3.50
Short-term Non-Convertible Loan [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate			12%	12%
Proceeds from short term debt				$ 516,450
Original issue discount percentage			10%	10%
Repayment of related party debt				$ 2,090

Schedule of Concerning Options

Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	17,540,209
Total exercisable, beginning balance	17,308,567
Shares, granted	230,000
Shares, exercised	(25,279)
Shares, expired/forfeited	(149,172)
Shares, ending balance	17,595,758
Total exercisable, ending balance	17,475,939
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	1,333,101
Weighted average price per share, beginning balance	$ 0.72
Shares, granted
Weighted average price per share, granted
Shares, exercised	(25,279)	(21,411)
Weighted average price per share, exercised	$ 0.69
Shares, expired/forfeited
Weighted average price per share, expired/forfeited
Shares, ending balance	1,307,822
Weighted average price per share, ending balance	$ 0.72
Total exercisable, ending balance	1,188,003
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	16,207,108
Weighted average price per share, beginning balance	$ 3.50
Shares, granted	230,000
Weighted average price per share, granted	$ 3.50
Shares, exercised
Weighted average price per share, exercised
Shares, expired/forfeited	(149,172)
Weighted average price per share, expired/forfeited	$ 3.50
Shares, ending balance	16,287,936
Weighted average price per share, ending balance	$ 3.50

Schedule of Loans Obligated to

Schedule of Loans Obligated to Issue Shares (Details) - USD ($)		6 Months Ended
	Oct. 01, 2019	Jun. 30, 2022
Short-Term Debt [Line Items]
Debt Instrument, Description	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Loans 1 [Member]
Short-Term Debt [Line Items]
Loan issuance date		Jul. 21, 2020
Loan principal		$ 115,000
Percentage of loan principal issuable		0.0435%
Defined date		Sep. 30, 2020
Debt Instrument, Description		Monthly
Loans 2 [Member]
Short-Term Debt [Line Items]
Loan issuance date		Sep. 21, 2020
Loan principal		$ 345,000
Percentage of loan principal issuable		0.0362%
Defined date		Nov. 16, 2020
Debt Instrument, Description		Weekly
Loans 3 [Member]
Short-Term Debt [Line Items]
Loan issuance date		Oct. 22, 2020
Loan principal		$ 115,000
Percentage of loan principal issuable		0.0652%
Defined date		Dec. 01, 2020
Debt Instrument, Description		Weekly
Loans 4 [Member]
Short-Term Debt [Line Items]
Loan issuance date		Oct. 21, 2021
Loan principal		$ 189,750
Percentage of loan principal issuable		0.0435%
Defined date		Jan. 02, 2022
Debt Instrument, Description		Monthly
Loans 5 [Member]
Short-Term Debt [Line Items]
Loan issuance date		Nov. 01, 2021
Loan principal		$ 189,750
Percentage of loan principal issuable		0.0435%
Defined date		Jan. 02, 2022
Debt Instrument, Description		Monthly

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 30, 2021
Class of Stock [Line Items]
options outstanding, shares	17,595,758				17,595,758		17,540,209
Number of options, exercisable	17,475,939				17,475,939		17,308,567
Interest expense	$ 1,835,589		$ 3,526,141		$ 4,414,750	$ 8,194,205
Number of common stock conversion of debt and interest		$ 350,500	$ 231,250	$ 118,000
Number of shares issued, value	191,303	472,900
Number of common stock for services rendered	67,800	$ 77,700		238,512
Stock option exercise, shares					25,279
Shares isused for options exercised, value	$ 17,443			$ 14,773
Lender [Member]
Class of Stock [Line Items]
Class of warrant or right, outstanding	100,000				100,000
Warrants term	3 years				3 years
Shares issued, price per share	$ 3.50				$ 3.50
Fair value of warrants					$ 87,436
Services Rendered [Member]
Class of Stock [Line Items]
Class of warrant or right, outstanding	30,000				30,000
Warrants term	3 years				3 years
Shares issued, price per share	$ 3.50				$ 3.50
Fair value of warrants					$ 39,761
Debt Extension [Member]
Class of Stock [Line Items]
Class of warrant or right, outstanding	100,000				100,000
Warrants term	3 years				3 years
Shares issued, price per share	$ 3.50				$ 3.50
Fair value of warrants					$ 132,537
Payment in Kind (PIK) Note [Member]
Class of Stock [Line Items]
Number of shares issued					782,600
Number of shares issued, value					$ 1,561,973
Payment in Kind (PIK) Note [Member] | Lenders [Member]
Class of Stock [Line Items]
Number of shares issued						1,642,982
Number of shares issued, value						$ 3,500,000
Dividends Paid In Kind [Member]
Class of Stock [Line Items]
Number of shares issued					118,274	56,067
Number of shares issued, value					$ 215,277	$ 114,298
Conversion of Debt Extension [Member]
Class of Stock [Line Items]
Number of common stock conversion of debt and interest, shares					140,200	139,700
Number of common stock conversion of debt and interest					$ 350,500	$ 349,250
Issued For Services Rendered [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares					77,000	112,400
Number of common stock for services rendered					$ 145,500	$ 238,512
New Conversion Debt [Member]
Class of Stock [Line Items]
Number of shares issued					114,000	120,000
Number of shares issued, value					$ 178,328	$ 112,877
Debt Settlement [Member]
Class of Stock [Line Items]
Stock option exercise, shares					25,279
Shares isused for options exercised, value					$ 17,433
Debt Extension [Member]
Class of Stock [Line Items]
Number of shares issued					320,900
Number of shares issued, value					$ 664,203
Accredited Investor and Consultants [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross					1,582,653
Stock Options [Member]
Class of Stock [Line Items]
options outstanding, shares	1,307,822				1,307,822		1,333,101
Weighted average exercise price	$ 0.72				$ 0.72		$ 0.72
Weighted average remaining term					7 years 2 months 19 days
Number of options, exercisable	1,188,003				1,188,003
Stock option exercise, shares					25,279	21,411
Stock options, exercise price			$ 0.69			$ 0.69
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued	106,400	214,500
Interest expense	$ 388,515				$ 1,553,765
Number of common stock conversion of debt and interest, shares		140,200	92,500	47,200
Number of common stock conversion of debt and interest		$ 1,402	$ 925	$ 472
Number of shares issued, value	$ 1,064	$ 2,145
Number of common stock for services rendered, shares	40,000	37,000		112,400
Number of common stock for services rendered	$ 400	$ 370		$ 1,124
Stock option exercise, shares	25,279			21,411
Shares isused for options exercised, value	$ 253			$ 214
Common Stock [Member] | Five Loans [Member]
Class of Stock [Line Items]
Number of shares issued	224,500				782,600
Warrant [Member]
Class of Stock [Line Items]
options outstanding, shares	16,287,936				16,287,936		16,207,108
Weighted average exercise price	$ 3.50				$ 3.50		$ 3.50
Number of common stock conversion of debt and interest
Number of shares issued, value
Number of common stock for services rendered
Stock option exercise, shares
Shares isused for options exercised, value
Warrant [Member] | New Conversion Debt [Member]
Class of Stock [Line Items]
Fair value of warrants						$ 1,700,000
Warrant issued			1,374,600			1,374,600
Warrant [Member] | New Conversion Debt [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrants term			3 years			3 years
Warrant exercise price			$ 3.50			$ 3.50
Warrant [Member] | New Conversion Debt [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrants term			5 years			5 years
Warrant exercise price			$ 5			$ 5
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Unvested stock based awards	$ 76,397				$ 76,397
Unrecognized compensation, period					7 months 13 days
Closing stock price	$ 1.74				$ 1.74
Options outstanding and exercisable intrinsic value	$ 1,348,013				$ 1,348,013
2021 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance								3,000,000
options outstanding, shares	1,307,822				1,307,822
Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	1,000,000				1,000,000
Convertible preferred stock, par value	$ 0.01				$ 0.01
Convertible preferred stock, shares issued	1,000,000				1,000,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	20,000				20,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	313,960				313,960
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	279,256				279,256
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	88,098				88,098
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	850				850		850
Convertible preferred stock, par value	$ 0.01				$ 0.01		$ 0.01
Convertible preferred stock, shares issued	300				300		300
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	500				500
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	240,000				240,000		240,000
Convertible preferred stock, par value	$ 0.01				$ 0.01		$ 0.01
Convertible preferred stock, shares issued	80,570				80,570		80,570
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	10,000				10,000		10,000
Convertible preferred stock, par value	$ 0.01				$ 0.01		$ 0.01
Convertible preferred stock, shares issued	10,000				10,000		10,000
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	21				21
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	6,250				6,250		6,250
Convertible preferred stock, par value	$ 0.01				$ 0.01		$ 0.01
Convertible preferred stock, shares issued	3,458				3,458		3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	15,000				15,000		15,000
Convertible preferred stock, par value	$ 0.01				$ 0.01		$ 0.01
Convertible preferred stock, shares issued	6,880				6,880		6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized	10,000				10,000		10,000
Convertible preferred stock, par value	$ 0.01				$ 0.01		$ 0.01
Convertible preferred stock, shares issued	8,645				8,645		8,649
Conversion of stock, shares converted					4
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares issued					4,400

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
	Oct. 01, 2019	Aug. 08, 2022	Jun. 30, 2022	Jun. 30, 2021
Subsequent Event [Line Items]
Proceeds from related party debt			$ 464,500	$ 171,600
Debt instrument description	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from related party debt		$ 203,000
Debt instrument description		due upon demand, 10% OID and 12% interest
Debt interest rate		12%
Subsequent Event [Member] | New Merchant Cash Loan [Agreement]
Subsequent Event [Line Items]
Proceeds from related party debt		$ 180,000
Debt periodic payment		$ 1,868
Debt frequency of periodic payment		for 130 days
Common stock issued for debt extension, shares		112,500
Convertible loans principal amount		$ 618,000
Loan period extension		two to six months